Pediatric HIV/AIDS Cohort Study

Pediatric HIV/AIDS Cohort Study
Name	Pediatric HIV/AIDS Cohort Study
Established	2005
Location	United States
Focus	Pediatric HIV, perinatal infection, antiretroviral therapy

Pediatric HIV/AIDS Cohort Study

The Pediatric HIV/AIDS Cohort Study (PHACS) is a multicenter longitudinal research initiative that follows children and adolescents with prenatal or perinatal exposure to Human immunodeficiency virus, including those who are HIV/AIDS-infected and HIV-exposed uninfected, to evaluate long-term outcomes of antiretroviral therapy exposure, comorbidities, and developmental trajectories. The cohort integrates clinical, laboratory, neurodevelopmental, and social data across numerous clinical sites to inform practice and policy affecting pediatric populations in the context of Centers for Disease Control and Prevention, National Institutes of Health, and international public health frameworks. PHACS links clinical care, translational science, and epidemiology to assess effects of in utero exposures on health across childhood and adolescence.

Overview

PHACS comprises multiple protocol cohorts organized to capture diverse clinical phenotypes, including the Surveillance Monitoring for ART Toxicities (SMARTT) and Adolescent Master Protocol (AMP), enrolling participants from pediatric clinics associated with academic centers such as Johns Hopkins Hospital, Massachusetts General Hospital, Children's Hospital of Philadelphia, Baylor College of Medicine, Columbia University Irving Medical Center, and University of California, San Francisco. The study collects biospecimens, clinical measures, imaging, and standardized neurocognitive assessments developed in consultation with experts from Harvard Medical School, Yale School of Medicine, University of Pittsburgh School of Medicine, and federal partners including the National Institute of Allergy and Infectious Diseases and the Eunice Kennedy Shriver National Institute of Child Health and Human Development. PHACS data have informed guidance from bodies such as the World Health Organization and national advisory groups on antiretroviral use in pregnancy and pediatrics.

History and Development

PHACS was initiated in response to gaps identified in pediatric outcomes after widespread prophylactic and therapeutic use of zidovudine, lamivudine, lopinavir/ritonavir, and other antiretroviral agents introduced in the late 20th and early 21st centuries. Early drivers included surveillance reports from the Centers for Disease Control and Prevention, cohort analyses from the Women's Interagency HIV Study, and longitudinal work at the Pediatric AIDS Clinical Trials Group and Perinatal HIV Research Unit. Initial funding and infrastructure were formalized through cooperative agreements with the National Institutes of Health and partnerships with academic sites, community advisory boards, and advocacy organizations such as Elizabeth Glaser Pediatric AIDS Foundation and AIDS Healthcare Foundation. Over time, PHACS expanded protocols in response to outcomes described in literature from institutions including Stanford University School of Medicine, University of Miami Miller School of Medicine, University of North Carolina at Chapel Hill, and global surveillance from the Joint United Nations Programme on HIV/AIDS.

Study Design and Methods

PHACS uses prospective cohort methods with biennial or annual visits incorporating standardized instruments from fields represented by contributors at Vanderbilt University Medical Center, Mount Sinai Hospital (Manhattan), University of Washington, and University of California, Los Angeles. Core elements include longitudinal measurement of viral load and CD4 count, pharmacokinetic sampling for drugs like tenofovir and efavirenz, neurodevelopmental batteries influenced by work at Columbia-Presbyterian Medical Center and Kennedy Krieger Institute, cardiac and metabolic assessments informed by collaborations with Cleveland Clinic and Mayo Clinic, and social determinants captured using tools validated in cohorts at Duke University School of Medicine and Northwestern University. Data management and biostatistics are supported by centers such as Fred Hutchinson Cancer Center and University of Minnesota, employing rigorous quality control, harmonized case report forms, and nested substudies for imaging, genomics, and pharmacogenomics.

Key Findings and Impact

PHACS has produced evidence on neurodevelopmental outcomes among children with in utero antiretroviral exposure, metabolic effects linked to specific regimens, and trajectories of cardiac and renal markers, cited by panels at American Academy of Pediatrics, U.S. Department of Health and Human Services, and advisory committees such as the Panel on Antiretroviral Guidelines for Adults and Adolescents. Results contributed to understanding risks associated with individual agents including reports paralleling findings from French Perinatal Cohort and Pediatric European Network for Treatment of AIDS. PHACS outputs have informed clinical guidelines, influenced perinatal ART recommendations from the World Health Organization and UNICEF, and shaped counseling resources developed by organizations such as March of Dimes and community groups. Publications have appeared alongside comparative analyses from cohorts at Imperial College London, University College London, and the Karolinska Institutet.

Ethical Considerations and Participant Protections

PHACS emphasizes informed consent and assent processes shaped by ethical frameworks from institutions including Georgetown University, University of Pennsylvania, and the Bioethics Commission. The study operates under institutional review board oversight at each participating site, privacy protections aligned with standards promulgated by the Office for Human Research Protections, and community engagement led by advisory groups comparable to those at Harvard School of Public Health and Columbia University Mailman School of Public Health. Special attention is given to disclosure, transition to adult care, and safeguarding against stigma in coordination with advocates such as Terrence Higgins Trust and local community health organizations.

Collaborations and Funding

PHACS is supported by collaborative funding from units of the National Institutes of Health, cooperative research networks including the International Maternal Pediatric Adolescent AIDS Clinical Trials Network, and partnerships with academic medical centers and community organizations. Contributions to laboratory science and data analysis have involved collaborations with Centers for Disease Control and Prevention, Fred Hutchinson Cancer Center, Broad Institute, and industry partners for drug assays. Funding and stakeholder engagement include foundations such as the Bill & Melinda Gates Foundation and policy input from agencies like the U.S. Food and Drug Administration, reflecting the interdisciplinary partnerships necessary to sustain long-term pediatric cohorts.

Category:HIV/AIDS research